Abstract
The results indicate that brain <sup>11</sup>C-PBR28 SUV is sensitive to TSPO genotype.
Introduction
The translocator protein (TSPO) serves as a critical biomarker for neuroinflammation, as its expression increases significantly during microglial activation. Positron Emission Tomography (PET) using tracers such as <sup>11</sup>C-PBR28 allows for the non-invasive visualization of this process. However, a common single-nucleotide polymorphism (rs6971) in the TSPO gene significantly alters tracer binding affinity, categorizing individuals into high-affinity (C/C), mixed-affinity (T/C), or low-affinity (T/T) binders.
While the "gold standard" for quantifying tracer uptake is the Total Volume of Distribution ($V_T$), this method requires invasive arterial blood sampling, which is often impractical for elderly or cognitively impaired patients. This study investigates whether the Standardized Uptake Value (SUV)—a simpler, non-invasive metric—is sufficiently sensitive to detect these genotype-driven differences in tracer binding.
Methodology
The study involved 32 older adults (mean age ~72 years) with varying cognitive statuses, including healthy controls, individuals with mild cognitive impairment, and those with Alzheimer’s disease. Participants underwent 90-minute dynamic PET scans with <sup>11</sup>C-PBR28 and 3-T MRI for anatomical reference.
Genotyping was performed using the Illumina HumanOmniExpress BeadChip, specifically targeting the rs6971 polymorphism. The primary outcome measure was the average SUV calculated from static images acquired 35–90 minutes post-injection across multiple brain regions of interest (ROIs), including the thalamus, cerebellum, and parietal cortex.
Results
The genetic distribution of the cohort consisted of 19 C/C (high-affinity), 12 T/C (mixed-affinity), and 1 T/T (low-affinity) subjects. Analysis revealed that the rs6971 genotype exerts a profound influence on tracer uptake. Specifically, mixed-affinity (T/C) carriers exhibited an average <sup>11</sup>C-PBR28 SUV signal approximately 30% lower than that of high-affinity (C/C) carriers.
This genotype effect was not restricted to a single area but was statistically significant across all brain regions examined ($P < 0.00005$ for the cerebellum and $P < 0.00003$ for the parietal cortex). The single T/T subject showed a drastically reduced signal, consistent with the "non-binder" status associated with this genotype.
Discussion and Conclusion
The findings demonstrate that SUV is a viable and sensitive proxy for more invasive quantification methods. The 30% difference observed between C/C and T/C genotypes using SUV matches the magnitude of difference previously reported using the arterial-based $V_T$ method. This confirms that TSPO PET data cannot be accurately interpreted without accounting for the subject's genotype, as a low signal could reflect either low inflammation or low binding affinity.
A limitation of this study is the small sample size, particularly the inclusion of only one T/T subject, which prevents a full characterization of the low-affinity group. Future research should focus on developing mathematical correction factors to adjust SUV data based on genotype. Such corrections would allow for the pooling of data from different genetic groups, increasing the statistical power of neuroinflammation studies in clinical populations.
Summary updated